Navidea Biopharmaceuticals, Inc. | Ekinops

Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.” Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud. For more information, please visit StockDayMedia.com Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy